Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avt29
- Development stage
- Phase 3
- Lead developer
- Alvotech
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravitreal
01
Overview
AVT29 is a recombinant fusion protein and an investigational biosimilar candidate to Eylea HD (aflibercept) 8 mg, developed by Alvotech. It is designed to bind vascular endothelial growth factors (VEGF), thereby inhibiting the binding and activation of VEGF receptors, which suppresses neovascularization and vascular permeability in the eye. This mechanism mirrors that of aflibercept, a widely used biologic for treating retinal diseases such as neovascular (wet) age-related macular degeneration (AMD), macular edema, and diabetic retinopathy. AVT29 has not yet received regulatory approval in any country[1][2][3][5][9].
- Other names
- AVT29AVT-29AVT 29
02
Targets
VEGFB (Vascular endothelial growth factor B)PGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on avt29.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avt29.